Introduction
Hypertensive cerebral hemorrhage is a common critical disease in the neurosurgerical field and even may threaten patients' life. The large hematoma with the significant mass effect is generally treated with surgery and the small ones with the conservative modality. The risk of basal ganglia hemorrhage increases in patients with hypertension. However, a proportion of patients with BGH have underlying vascular abnormalities, and these patients may require a different treatment approach 
Methods
A total of 595 patients with hematoma between 25 to 35ml in volume (380 males and 215 females) were enrolled into this study with an average age of 57 years (range 27 to 75 years).
All patients had hypertension histories and were treated with 3 methods: the conservative therapy (n=361), evacuation of the hematoma with the microinvasive craniopunture within 6 (n=89) or 6-48h (n=145) following attack.
Clinical manifestations
All patients experienced a sudden attack, manifesting with hemiplegia, aphasia, nausea, vomiting or slight conscious disturbance but no any brain hernia signs such as mydriasis.
Imaging examinations
CT confirmed the hemorrhage in the basal ganglia region and the supratentorial hematoma volume of 25-35ml (30±5ml) (calculated according to the Coniglobus formula). The hematoma was primarily located in the basal ganglia region but also broke into the ventricle in a few of patients without ventricular enlargement.
Selection of methods
All patients met the above criteria and following patients were excluded from this study: 1) with coagulation disturbance;
2) with long-term administration of anticoagulant agents; 3) in the dying situation which manifested with cerebral hernia and bilateral mydriasis; or 4) with bleeding inducing tumor, trauma, The cortex was punctured under direct vision and the puncturing depth was determined by the hematoma volume. The drainage tube was placed just in the middle of the hematoma and 1cm away from the inner wall of the hematoma cavity. During surgery, the blood needed no aspiration but naturally outflowed with cerebral pulsation to reduce the recurrent hemorrhage. Urokinase (10,000 units/5ml, per day) was injected into the hematoma cavity after 24h following attack, retained for 2 to 4h according to patients' tolerance and then opened. Cranial CT was reexamined two to six days later. 2) Hematoma disappearance: it was defined that the intracerebral hematoma decreased by more than 90%. For patients receiving conservative therapy with no complete hematoma absorption but meeting discharge criteria, the hematoma
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disappearing time was estimated via the hematoma absorbing speed (ml/day) by calculating the hematoma volume difference according to admission and discharge CT findings.
3) Hospital costs: the average cost was the cost for evacuation of the hematoma with the microinvasive craniopuncture within 6h following attack and the ratio of individual's costs to the average cost was calculated. 
Results

Long-term efficacy
Patients were followed up for three months following surgery. A good prognosis was observed in 335 of patients with conservative therapy (92.8%), 77 of patients with surgery within 6h
following attack (86.5%) and 139 of patients with surgery within 6-24h following attack (95.8%). A significant difference was noted in surgery within 6h following attack as compared to surgery within 6-24h following attack and conservative therapy (p<0.05) (Table 1) but not noted between patients with conservative therapy and those with surgeries (p>0.05) ( Table 2) . (1) Evacuation of the hematoma with the microinvasive craniopuncture within 6h following attack; (2) Evacuation of the hematoma with the microinvasive craniopuncture within 6-24h following attack. *p<0.05, the conservative group vs. the surgical group (2). 
Comparison of hospital stays and costs as well as hematoma disappearing time
Evacuation of the hematoma with the microinvasive craniopuncutre could significantly reduce hospital stays and costs as well as hematoma disappearing time compared to the conservation therapy (p<0.05) ( Table 3) . 
Discussion
Hypertensive cerebral hemorrhage usually occurs in the basal ganglia region, manifesting with the three deflective sign, and generally stops within 20 to 30 minutes 1 . However, there is still active or recurrent hemorrhage 2 , of which, most stops within 6h when the coagulation mechanism fully functions and the blood pressure is stable 3 . The hematoma can directly damage local nerve fibers, leading to the cerebral ischemia and hypoxia. Within 6 to 48h, patient's blood pressure and emotion are stable, hemorrhage had coagulated, the hematoma is in a relatively stable status, the cerebral edema is not severe, recurrent hemorrhage is less possible and patients are relatively safe. Cerebral hemorrhage is a relatively rapid process. It can immediately induce the displacement of brain tissues and rapid hematoma removal can cause reposition of these brain tissues, both damaging brain tissues. However, the damages can be avoided if the surgery is conducted in 6-48h later. In spite of a long course, absorption of hematoma with drugs is a relatively slow self-repair process, which can not induce additional injuries. Even though position is very accurate and the trauma is minimal, it is inevitable for nerve fibers and nuclei to injury, which may increase the incidence of complications. This side effect offset the benefit of the complete hematoma removal to a certain extent, which can be confirmed by causes why the micropuncture and evacuation cannot improve the long-term efficacy.
We also observed that evacuation of the hematoma with the microinvasive craniopuncture had significant benefits compared to the conservative therapy. In China, patients with hypertensive cerebral hemorrhage are primarily distributed in the rural areas. The surgery procedure is a favorable option for patients with economic difficulty and has the following advantages:
1) It is simple to operate and time-saving (around 40 minutes), especially suitable for primary hospitals.
2) The hematoma should be accurately positioned and for this, the stereotactic technique or CT guidance was used in this study. The drainage tube should be placed at the center of the hematoma to be beneficial for drainage.
3) Urokinase directly acts on the intrinsic fibrionlytic system to catalyze the conversion from plasminogen to plasmin and also can increase the activity of ADP enzyme, inhibit ADP-induced platelet aggregation and prevent thrombosis. Therefore, it shows a fast and good efficacy on the newly-formed thrombus. Additionally, following attack.
Conclusions
The treatment modality for supratentorial hematoma with the critical volume should be determined according to patient's age, nerve functions, bleeding volume and site and concern of the patient and families. Risks of complications such as recurrent hemorrhage can be significantly increased when surgery is conducted within 6h following attack but not within 6-48h following attack. Therefore, the latter is considered the best option for hemorrhage of basal ganglia region with the critical volume.
